Literatur
-
1 Schaberg T, Kaufmann S. Infektion. In: Siegenthaler W, Hrsg. Klinische Pathophysiologie. Stuttgart: Thieme 2001: 565-590
-
2 Nicholson K G. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science 1998: 219-264
-
3
Couch R B.
Prevention and treatment of influenza.
N Engl J Med.
2002;
343
1778-1787
-
4
Hak E, Verheij T J, van Essen G A. et al .
Prognostic factors for influenza-associated hospitalization and death during an epidemic.
Epidemiol Infect.
2001;
126(2)
261-268
-
5
Robert Koch-Institut .
Vorbereitung auf die Influenza-Saison 2001/2002.
Epidemiol Bull.
2001;
36/2001
271-273
-
6
Robert Koch-Institut .
Zur Surveillance der Influenza in Deutschland.
Epidemiol Bull.
2001;
36/2001
274-275
-
7
Robert Koch-Institut .
Erste Einschätzung der Influenza-Saison 2001/2002.
Epidemiol Bull.
2002;
17/2002
135-136
-
8
Fock R, Bergmann H, Bußmann H. et al .
Influenza pandemic: preparedness planning in Germany.
Euro Surveillance.
2002;
7(1)
1-5
-
9
Wutzler P.
Aktuelle Probleme bei der Influenza-Bekämpfung.
Chemotherapie J.
2002;
11
154-156
-
10
Atmar R L, Baxter B D, Dominguez E A. et al .
Comparison of reverse transcription-PCR with tissue culture and other rapid diagnostic assays for detection of type A influenza virus.
J Clin Microbiol.
1996;
34
2604-2606
-
11
Noyola D E, Clark B, O'Donnell F T. et al .
Comparison of a new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, and culture for rapid detection of influenza A and B viruses in nasal wash specimens.
J Clin Microbiol.
2000;
38(3)
1161-1165
-
12
Monto A S, Gravenstein S, Elliott M. et al .
Clinical signs and symptoms predicting influenza infection.
Arch Intern Med.
2000;
160(21)
3243-3247
-
13
van Elden L J, van Essen G A, Boucher C A. et al .
Clinical diagnosis of influenza virus infection: evaluation of diagnostic tools in general practice.
Br J Gen Pract.
2001;
51(469)
630-634
-
14
Bryson Y J, Monahan C, Pollack M. et al .
A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis.
J Infect Dis.
1980;
141(5)
543-547
-
15
Hayden F G, Sable C A, Connor J D. et al .
Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection.
Antivir Ther.
1996;
1(1)
51-56
-
16
Karlsson M, Reichard O, Linde A. et al .
Amantadine for prophylaxis against influenza A.
Scand J Infect Dis.
1987;
19(1)
141-142
-
17
Dolin R, Reichman R C, Madore H P. et al .
A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection.
N Engl J Med.
1982;
307(10)
580-584
-
18
Jefferson T, Demicheli V, Rivetti D. et al .
Cochrane reviews and systematic reviews of economic evaluations. Amantadine and rimantadine in the prevention and treatment of influenza.
Pharmacoeconomics.
1999;
16 Suppl 1
85-89
-
19 Jefferson T O, Demicheli V, Deeks J J. et al .Amantadine and rimantadine for preventing and treating influenza A in adults. In: The Cochrane Library, 4. Oxford: Update Software 2001
-
20
Hayden F G, Belshe R B, Clover R D. et al .
Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.
N Engl J Med.
1989;
321(25)
1696-1702
-
21
Masuda H, Suzuki H, Oshitani H. et al .
Incidence of amantadine-resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan.
Microbiol Immunol.
2000;
44(10)
833-839
-
22 Jefferson T, Demicheli V, Deeks J. et al .Neuraminidase inhibitors for preventing and treating influenza in healthy adults. In: The Cochrane Library, 4. Oxford: Update Software 2001
-
23
Hayden F G, Osterhaus A D, Treanor J J. et al .
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
N Engl J Med.
1997;
337(13)
874-880
-
24
Treanor J J, Hayden F G, Vrooman P S. et al .
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
JAMA.
2000;
283(8)
1016-1024
-
25
Monto A S, Fleming D M, Henry D. et al .
Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.
J Infect Dis.
1999;
180(2)
254-261
-
26
Hayden F G, Gubareva L V, Monto A S. et al .
Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.
N Engl J Med.
2000;
343(18)
1282-1289
-
27
Monto A S, Robinson D P, Herlocher M L. et al .
Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial.
JAMA.
1999;
282(1)
31-35
-
28
Hayden F G, Atmar R L, Schilling M. et al .
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
N Engl J Med.
1999;
341(18)
1336-1343
-
29
Parker R, Loewen N, Skowronski D.
Experience with oseltamivir in the control of a nursing home influenza B outbreak.
Can Commun Dis Rep.
2001;
27(5)
37-40
-
30
Bowles S K, Lee W, Simor A E. et al .
Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999 - 2000.
J Am Geriatr Soc.
2002;
50(4)
608-616
-
31
Nichol K L, Wuorenma J, Von Sternberg T.
Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens.
Arch Intern Med.
1998;
158
1769-1776
-
32
Deguchi Y, Takasugi Y, Tatara K.
Efficacy of influenza vaccine in the elderly in welfare nursing homes: reduction in risks of mortality and morbidity during an influenza A (H3N2) epidemic.
J Med Microbiol.
2000;
49(6)
553-556
-
33
Nichol K L, Margolis K L, Wuorenma J. et al .
The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.
N Engl J Med.
1994;
331
778-784
-
34
Christenson B, Lundbergh P, Hedlund J. et al .
Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study.
Lancet.
2001;
357(9261)
1008-1011
-
35
Nordin J, Mullooly J, Poblete S. et al .
Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans.
J Infect Dis.
2001;
184(6)
665-670
-
36
Demicheli V, Rivetti D, Deeks J J. et al .
Vaccines for preventing influenza in healthy adults.
Cochrane Database Syst Rev.
2001;
(4)
CD001269
-
37
Nichol K L, Margolis K L. et al .
Effectiveness of influenza vaccine in the elderly.
Gerontology.
1996;
42(5)
274-279
-
38
Nichol K L, Baken L, Nelson A.
Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease.
Ann Intern Med.
1999;
130(5)
397-403
-
39
Nichol K L, Goodman M.
The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years.
Pharmacoeconomics.
1999;
16 Suppl 1
63-71
-
40
Nichol K L, Margolis K L, Lind A. et al .
Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial.
Arch Intern Med.
1996;
156
1546-1550
-
41
Bridges C B, Thompson W W, Meltzer M I. et al .
Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.
JAMA.
2000;
284(13)
1655-1663
-
42
Leighton L, Williams M, Aubery D. et al .
Sickness absence following a campaign of vaccination against influenza in the workplace.
Occup Med (Lond).
1996;
46(2)
146-150
-
43
Postma M J, Jansema P, van Genugten M L. et al .
Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.
Drugs.
2002;
62(7)
1013-1024
-
44
Nichol K L.
Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.
Arch Intern Med.
2001;
161(5)
749-759
-
45
Allsup S J, Gosney M, Regan M. et al .
Side effects of influenza vaccination in healthy older people: a randomised single-blind placebo-controlled trial.
Gerontology.
2001;
47(6)
311-314
-
46
Lasky T, Terracciano G J, Magder L. et al .
The Guillain-Barré syndrome and the 1992 - 1993 and 1993 - 1994 influenza vaccines.
N Engl J Med.
1998;
339
1797-1802
-
47
Beyer W E, de Bruijn I A, Palache A M. et al .
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies.
Arch Intern Med.
1999;
159(2)
182-188
-
48
Centers for Disease Control and Prevention .
Influenza and pneumococcal vaccination levels among adults aged > or = 65 years - United States, 1997.
JAMA.
1998;
280
1818-1819
-
49
Robert Koch-Institut .
Teilnahme an Influenza- und Pneumokokken-Schutzimpfung.
Epidem Bull.
2002;
16/2002
127-131
-
50
Nichol K L, Hauge M.
Influenza vaccination of healthcare workers.
Infect Control Hosp Epidemiol.
1997;
18(3)
189-194
-
51
STIKO .
Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand Juli 2002.
Epidemiol Bull.
2002;
28
227-242
-
52
Wilde J A, McMillan J, Serwint J. et al .
Effectiveness of influenza vaccine in health care professionals: a randomized trial.
JAMA.
2002;
281
908-913
-
53
Robert Koch-Institut .
Influenza-Schutzimpfung im Rahmen einer Aktion angeboten.
Epidemiol Bull.
2002;
38/2002
321-323
-
54
Kiderman A, Furst A, Stewart B. et al .
A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997 - 98.
J Clin Virol.
2001;
20(3)
155-161
-
55
Jackson L A, Austin G, Chen R T. et al .
Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors.
Vaccine.
2001;
19(32)
4703-4709
-
56
Mendelman P M, Cordova J, Cho I.
Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults.
Vaccine.
2001;
19(17 - 19)
2221-2226
-
57
Belshe R B, Gruber W C.
Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
Philos Trans R Soc Lond B Biol Sci.
2001;
356(1416)
1947-1951
-
58
Treanor J J, Kotloff K, Betts R F. et al .
Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.
Vaccine.
1999;
18(9 - 10)
899-906
-
59
Longini I M, Halloran M E, Nizam A. et al .
Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control.
Vaccine.
2000;
18(18)
1902-1909
Prof. Dr. T. Schaberg
Zentrum für Pneumologie · Diakoniekrankenhaus Rotenburg
Verdener Str. 200
27356 Rotenburg
eMail: schaberg@diako-online.de
